Immunogenicity of semisynthetic human insulin in man. Long-term comparison with porcine monocomponent insulin
Autor: | C. Jaminet, Alfred S. Luyckx, Pierre Lefebvre, André Scheen, Daubresse Jc |
---|---|
Rok vydání: | 1986 |
Předmět: |
Adult
Male medicine.medical_specialty Time Factors Swine Endocrinology Diabetes and Metabolism medicine.medical_treatment Antibodies Islets of Langerhans chemistry.chemical_compound Endocrinology Internal medicine Diabetes mellitus Internal Medicine medicine Animals Humans Insulin Prospective Studies Circadian rhythm Prospective cohort study biology business.industry C-peptide Immunogenicity General Medicine Middle Aged medicine.disease Diabetes Mellitus Type 1 chemistry Metabolic control analysis Antibody Formation biology.protein Female Antibody business |
Zdroj: | Acta Diabetologica Latina. 23:99-106 |
ISSN: | 1432-5233 0001-5563 |
DOI: | 10.1007/bf02624669 |
Popis: | The levels of circulating IgG-insulin antibodies were determined in two groups of diabetic patients before and at 3-month intervals after starting insulin treatment either with monocomponent porcine insulin (n = 17) or with human semisynthetic insulin (SH) (n = 16). Patients were followed during 15.1 +/- 1.0 and 19.9 +/- 1.1 months, respectively (m +/- SEM). In addition, the quality of metabolic control and residual B-cell function were evaluated in the group under treatment with SHI. The percentage of patients who remained antibody-free after 12-21 months of treatment was 67.75% in the human insulin-treated group and only 25-43% in the one receiving porcine insulin (p less than 0.01). Moreover, insulin antibody titers, when present, were usually lower in subjects treated with human insulin. In SHI-treated patients: metabolic control was excellent during the first months of treatment as evidenced by values of mean daily blood glucose (7.3 +/- 0.6 mmol/l), M-index according to Schlichtkrull (7.4 +/- 2.4) and Hb1c (6.8 +/- 0.6%); residual B-cell function, evaluated at 3-month intervals by a circadian profile of plasma C-peptide did not decrease throughout the study; and a significant deterioration of blood glucose control occurred after 18 months of treatment, which might have been due to a less intensive supervision of the patients by the physicians and/or less careful attention by the patients themselves. This observation confirms the need for a continuous education of the patients regardless of the type of insulin used. |
Databáze: | OpenAIRE |
Externí odkaz: |